Аssociation of polymorphisms rs20325282 in ABCB1 gene and rs1695 in GSTP1 gene with the toxic effects during chemotherapy with cyclophosphamide and doxorubicin in breast carcinoma
- brest cancer,
- GSTP1 gene polymorphism,
- toxic effects
How to Cite
Copyright (c) 2019 Ilir Ismail
This work is licensed under a Creative Commons Attribution 4.0 International License.
Breast cancer is a major morbidity and mortality factor and is among the most frequent female neoplasms globally. Combined cyclophosphamide and doxorubicin adjuvant chemotherapy is frequently associated with a series of toxic effects of different grades and clinical significance. Constitutive polymorphisms in the genes involved in detoxification and metabolism of chemotherapeutics play a key role in toxic effects predisposition. The main goal of this study was to determine the genetic association of polymorphisms rs20325282 in ABCB1 gene and rs1695 (A313G) in GSTP1 gene with occurrence of toxic effects during chemotherapy with cyclophosphamide and doxorubicin in patients with breast carcinoma. Material and methods: The polymorphisms were genotyped in DNA samples derived from 110 cases of breast cancer treated adjuvantly with cyclophosphamide and doxorubicin, after providing a signed consent from each patient. Statistical analyses were performed comparing the clinical data regarding the toxic effects and adverse reactions with the freqencies of the genotypes and alleles of both polymorphisms. Results: the analyses indicated that polymorphisms rs20325282 in ABCB1 gene and rs1695 in GSTP1 have a predictive value in determing the probability and/of risk of occurence of neutropenia, leukopenia and any toxic effect except nausea and vomiting. The polymorphism rs1695 in GSTP1 has a predictive value in estimation of the risk for chemotherapy-induced anemia. Conclusions: these findings could be used prospectively for adjustment and personalisation of the chemotherapy according to the individual genotypes combination in each patient.
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49(6):1374-403.
- Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289(24):3243-53.
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490(7418):61-70.
- Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102(6):1003-9.
- Ikeda M, Tsuji D, Yamamoto K, Kim YI, Daimon T, Iwabe Y, Hatori M, Makuta R, Hayashi H, Inoue K, Nakamichi H, Shiokawa M, Itoh K. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet 2015; 30(2):149-53.
- Pinto N, Ludeman SM, Dolan ME. Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 2009; 10(12):1897-903.
- Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Ðµt al. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 2014; 14(3):241-7.
- Ge J, Tian AX, Wang QS, Kong PZ, Yu Y, Li XQ, et al. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS One 2013; 8(6):e67589.
- Wang J, Wang T, Yin GY, Yang L, Wang ZG, Bu XB. Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer. Genet Mol Res 2015; 14(3):11126-32.
- Ferreira RJ, dos Santos DJ, Ferreira MJ. P-glycoprotein and membrane roles in multidrug resistance. Future Med Chem 2015; 7(7):929-46.
- National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, NIH Publication No. 09-5410, DHHS, 2010.
- Liu J, Zhou Z, Hodgkinson CA, Yuan Q, Shen PH, Mulligan CJ, et al. Haplotype-based study of the association of alcohol-metabolizing genes with alcohol dependence in four independent populations. Alcohol Clin Exp Res. 2011;35(2):304–316.
- Tran A, Bournerias F, Le Beller C, Mir O, Rey E, Pons G, Delahousse M, Tréluyer JM. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. Br J Clin Pharmacol 2008; 65(2):279-80.
- Zhang BL, Sun T, Zhang BN, Zheng S, Lí¼ N, Xu BH, Wang X, Chen GJ, Yu DK, Lin DX. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl) 2011; 124(2):199-204.
- Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther 2013; 17(6):371-9.
- Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY, Hou MF. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 2009; 404(2):160-5.
- Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, et al. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol 2014;74(4):667–74.
- Chaturvedi P, Tulsyan S, Agarwal G, Lal P, Agarwal S, Mittal RD, Mittal B. Influence of ABCB1 genetic variants in breast cancer treatment outcomes. Cancer Epidemiol 2013; 37(5):754-61.
- Ji M, Tang J, Zhao J, Xu B, Qin J, Lu J. Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther 2012; 13(5):264-71.